Dengvaxia

Dengvaxia

Manufacturer:

Sanofi Pasteur

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Dengue tetravalent vaccine (live, attenuated) (4.5-6 log10 CCID50 of each serotype of the CYD dengue virus 1, 2, 3, & 4)
Indications/Uses
Protection against dengue disease caused by dengue virus serotypes 1, 2, 3 & 4 for adults, adolescents & childn 9-45 yr.
Dosage/Direction for Use
SC Adult & childn 3 inj of 0.5 mL each at 6-mth intervals.
Contraindications
Hypersensitivity. Allergic reaction after prior to administration. Mild to high fever or acute disease. Weakened immune system eg, genetic defect, HIV infection or therapies affecting the immune system (high-dose corticosteroids or chemotherapy). Pregnancy & lactation.
Special Precautions
Not recommended for individuals who have never been infected by dengue virus before vaccination. Do not substitute for protection against mosquito bites. Postpone administration for 4 wk after immunosuppressive treatment. Patients that might have a dengue infection. Patients traveling or living in areas w/ dengue infection is not recommended to have Dengvaxia vaccination. Childn <9 yr.
Adverse Reactions
Difficulty in breathing, blueness of the tongue or lips, rash, swelling of the face or throat, low BP causing dizziness or collapse, sudden & serious malaise w/ drop in BP causing dizziness & loss of consciousness, accelerated heart rate associated w/ resp disorders. Headache, myalgia, malaise, asthenia, inj site pain, fever.
Drug Interactions
Drugs that suppress immune system eg, corticosteroids or chemotherapy.
ATC Classification
J07B - VIRAL VACCINES ; Used for active immunizations.
Presentation/Packing
Form
Dengvaxia powd for inj
Packing/Price
(+ solvent in single-dose pre-filled syringe) 0.5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in